Tommaso Lorenzona,
Maria Vescovoa,
Michele Maiullaria,
Giovanni Tonon
b,
Nuno Reis Conceição
c,
Sónia A. C. Carabineiro
cd,
Abdallah G. Mahmoud
d,
Martin C. Dietl
e,
Nicola Demitri
f,
Laura Orian
a,
Pablo A. Nogara
g,
Isabella Caligiurih,
Flavio Rizzolio
ah,
A. Stephen K. Hashmi
ei,
Fabiano Visentin
b and
Thomas Scattolin
*a
aDipartimento di Scienze Chimiche, Università degli Studi di Padova, Via Marzolo 1, 35131 Padova, Italy. E-mail: thomas.scattolin@unipd.it
bDipartimento di Scienze Molecolari e Nanosistemi, Università Ca’ Foscari, Campus Scientifico Via Torino 155, 30174 Venezia-Mestre, Italy
cCentro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisboa, Portugal
dLAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
eOrganisch-Chemisches Institut, Heidelberg University, Im Neuenheimer Feld 270, 69120 Heidelberg, Germany
fElettra-Sincrotrone Trieste, S.S. 14 Km 163.5 in Area Science Park, 34149 Basovizza, Trieste, Italy
gDepartamento de Bioquímica e Biologia Molecular, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, RS, Brazil
hPathology Unit, Centro di Riferimento Oncologico di Aviano (C.R.O.), IRCCS Via Franco Gallini 2, 33081, Aviano, Italy
iChemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
First published on 1st May 2025
In this study, we report the synthesis and characterization of novel organopalladium complexes featuring 1,3,5-triaza-7-phosphaadamantane (PTA)-based ligands, including several cationic derivatives prepared as hexafluorophosphate salts to prevent halide exchange reactions. The complexes incorporate diverse organopalladium fragments—Pd(II)-vinyl, Pd(II)-butadienyl, Pd(II)-allyl, Pd(II)-imidoyl, Pd(II)-aryl, and Pd(0)-alkene—many of which have recently shown promising antitumor activity. Most reactions proceeded rapidly at room temperature under aerobic conditions using non-anhydrous solvents. Biological evaluation against ovarian cancer (A2780), cisplatin-resistant ovarian cancer (A2780cis), triple-negative breast cancer (MDA-MB-231), glioblastoma (U87), and non-cancerous fibroblasts (MRC-5) revealed the remarkable cytotoxicity of the complexes, particularly those with Pd(II)-butadienyl, Pd(II)-aryl, and Pd(0)-alkene fragments. These compounds demonstrated activity comparable to or exceeding cisplatin, with some showing up to two orders of magnitude greater efficacy. Importantly, the complexes were highly selective for cancer cells, exhibiting minimal toxicity toward MRC-5 fibroblasts, unlike cisplatin. Complex 14b, that contains a Pd(0)-alkene fragment and two MePTA+ ligands, was the only one that exhibited excellent cytotoxicity across all cancer cell lines, including glioblastoma. These findings underscore the potential of PTA-based organopalladium complexes as selective anticancer agents, warranting further in vitro and in vivo studies, as well as mechanistic investigations.
This coordination capability allows PTA to form stable complexes with a broad array of metals, including transition metals.1–13 The possibility to modify the electronic properties of PTA by introducing different substituents on the nitrogen atoms further enhances its versatility, enabling the fine-tuning of ligands for specific catalytic, biological or material applications.14–20
In the realm of medicinal chemistry, PTA metal complexes have shown significant potential, particularly in the development of new anticancer agents.1–3 The stability and unique electronic properties of PTA allow for the formation of complexes with enhanced biological activity and reduced toxicity compared to traditional metal-based chemotherapeutic agents. For example, PTA-platinum complexes are being investigated as alternatives to conventional platinum-based drugs, offering improved efficacy and fewer side effects.19,21,22 However, the most famous class of biologically active PTA complexes is the RAPTA (Ruthenium Arene PTA) family.23–30 These compounds have been extensively investigated as promising antimetastatic agents, with RAPTA-C (featuring a cymene ligand) and RAPTA-T (featuring a toluene ligand) emerging as the leading candidates.31–38 Their antimetastatic activity appears to be linked to their ability to form covalent bonds with key proteins within cancer cells.
Much less explored is the coordination chemistry of PTA in organopalladium compounds. These organometallic derivatives have shown promising antitumor activity, especially towards in vitro, ex vivo, and in vivo ovarian cancer models, with some compounds exhibiting reduced cytotoxicity against non-cancerous cells.39–50
Our group has recently reported the synthesis and antitumor activity of compounds containing various organopalladium fragments such as Pd(II)-allyl,40,46 palladacyclopentadienyl,45 Pd(II)-imidoyl,47 Pd(II)-vinyl,39 Pd(II)-butadienyl,39 Pd(II)-aryl49 and Pd(0)-alkene.41
In this work, we propose to utilize some of these promising organopalladium fragments as tools to evaluate the influence of the nature of the PTA-based ligand used on the antitumor activity of the resulting complexes. Specifically, we will compare the activity of complexes containing PTA with those of homologous complexes that contain cationic PTA derivatives (Fig. 1).
It is well known that the charge of a complex has important implications for its therapeutic activity. In principle, cationic complexes or those containing cationic groups (e.g., ammonium or phosphonium substituents) tend to exhibit good cellular uptake and primary localization in the mitochondria, whereas anionic complexes exhibit reduced cellular uptake.51–53
Therefore, the use of cationic derivatives of PTA should significantly shift the localization of the complexes studied in this work towards mitochondria, even in the presence of organopalladium fragments that typically target DNA (e.g., Pd(II)-aryl)49 or promote cell death mechanisms other than apoptosis, such as ferroptosis (e.g., Pd(II)-butadienyls).39
Among the cationic derivatives of PTA examined in this work, one exhibits a structure very similar to acetylcholine. This ligand preserves the main characteristics of this important biomolecule, in conjunction with a suitable coordination site for the metal.19 Moreover, with the aim of studying these complexes as potential therapeutic agents against different types of cancer, including brain cancer, they could exploit organic cation transporters (OCTs) expressed in the blood–brain barrier (BBB) to cross from the blood to the central nervous system, thus acting as Trojan horses for biologically active organopalladium fragments.54,55
Compound b was chosen because it contains the simplest organic substituent (methyl group), thus representing the cationic version of PTA with the most comparable steric hindrance. Compound c, as previously mentioned, exhibits a structure very similar to acetylcholine, whereas derivatives d and e were selected because their copper and gold complexes have recently shown interesting catalytic and anticancer properties, respectively.57,58
To enable a proper comparison among the target organopalladium complexes, we decided to convert all the cationic PTA derivatives into their hexafluorophosphate congeners. This ensures that all final complexes contain the same non-coordinating counterion, therefore preventing potential halide exchange at the metal center.
This synthetic step proceeds quickly and with good yields, as the final products (b–e) precipitate from the aqueous solution containing KPF6 and potassium halide (co-product).
The hexafluorophosphate PTA-based ligands (b–e) were thoroughly characterized by 1H and 31P NMR analyses.
Particularly diagnostic are the 31P NMR spectra, where a singlet can be observed between −80 and −87 ppm, which is markedly downfield shifted with respect to that of neutral PTA (δ ≈ −102 ppm). In addition, the diagnostic septet present at ca. −144 ppm indicates the presence of the hexafluorophosphate anion.
Inspired by this recent contribution, we decided to synthesize a selection of new Pd(II)-vinyl and -butadienyl complexes bearing cationic PTA-based ligands. The procedure, which differs from the one previously proposed for using acetonitrile instead of dichloromethane, involves a direct reaction between the selected PTA-based ligand (b–e) and the palladium precursors 1–2. These precursors bear the labile 2-methyl-6-(phenylthiomethyl)pyridine ligand and vinyl or butadienyl fragments, respectively (Scheme 2A and B). Acetonitrile was chosen as the solvent since it can dissolve both the phosphine ligands b–e, which are insoluble in dichloromethane, and the palladium precursors 1–2.
![]() | ||
Scheme 2 Synthetic procedure to Pd(II)-vinyl (A), Pd(II)-butadienyl (B), Pd(II)-aryl (C), Pd(II)-allyl (D), Pd(II)-imidoyl (E) and Pd(0)-alkene (F) complexes. |
All reactions reached completion within 30 minutes and the target complexes were fully characterized by NMR and elemental analysis.
The 31P NMR spectra of the products exhibit, in addition to the septet at ca. −144 ppm of the hexafluorophosphate anion, one singlet at ca. −40 ppm. This clearly indicates both the coordination of PTA-based ligands (Δδ ≈ 40 ppm with respect to the free ligand) and the mutual trans position of these ligands (the hypothetical cis isomer would generate two doublets).
The 1H NMR spectra confirm the nature of the obtained products, showing the methyl protons of the vinyl and butadienyl fragments (1.8–3.9 ppm), as well as signals of the methylene protons (NCH2N and NCH2P) of the triaza-phosphaadamantane moiety as multiplets between 4 and 5 ppm. Additionally, all characteristic signals of the alkyl substituents of the different PTA derivatives are present. Notably, all aforementioned signals exhibit chemical shifts different from those of the two starting reagents.
The primary biological target of neutral Pd(II)-aryl complexes appears to be DNA. In particular, for complexes bearing chelating diphosphine ligands, the interaction with the biological target and the consequent anticancer activity are closely related to the bite angle of the ancillary ligand. Specifically, smaller bite angles ensure higher DNA affinity and greater cytotoxicity of the compounds.49
Encouraged by these findings, we questioned whether it would be possible to expand the toolbox of neutral Pd(II)-aryl complexes by employing PTA in place of the classical triphenylphosphine, which was used in our recent study.49 Moreover, with the final goal of evaluating the influence of complex charge on the biological properties of this class of compounds, we selected [Me-PTA]PF6 (b) as a cationic ligand to anchor to the Pd(II)-aryl fragment. Specifically, the complexes examined feature two PTA-based ligands, a 4-nitrophenyl or a 4-trifluoromethyl group, and one iodide ligand.
The reaction between Pd(II)-aryl precursors 5–6, which contain the labile N,N,N′,N′-tetramethylethylenediamine (tmeda) ligand, and two equivalents of PTA (a) or [Me-PTA]PF6 (b), yielded the target complexes 7a–b and 8a in good to excellent yields and purity. As usual, the reactions with the PTA ligand were carried out in dichloromethane, while those with the cationic [Me-PTA]PF6 (b) derivative were performed in acetonitrile, systematically achieving completion within 30 minutes at room temperature (Scheme 2C and D). Notably, in the case of complex 8b, some side-products difficult to eliminate were detected. For this reason, this complex was excluded from full characterization as well as from biological studies.
The new Pd(II)-aryl complexes 7a–b and 8a–b were fully characterized by NMR, XRD, and elemental analyses.
Taking the neutral complexes 7a and 8a as examples, the coordination of the PTA ligands and their mutual trans position can be confirmed by the presence of a singlet in the 31P NMR spectrum at ca. −70 ppm (Δδ ≈ 30 ppm with respect to the free PTA ligand). Additionally, in the 1H NMR spectra signals corresponding to the methylene protons of PTA (PCH2N as a singlet at ca. 4 ppm and NCH2N as a multiplet at 4.3–4.5 ppm) are observed. In the aromatic region, two signals are detected for the protons of the 4-nitrophenyl or 4-trifluoromethyl fragments. Consistently, in the 13C NMR spectra, the methylene carbons PCH2N and NCH2N resonate as doublets at 52 and 73 ppm, respectively, along with all carbons of the aryl fragment.
Similar considerations can be applied to the dicationic complex 7b. Particularly diagnostic is the 31P NMR spectrum, which present a singlet at −50 ppm, in addition to the septet at −144 ppm of the hexafluorophosphate anion.
Finally, in the case of complexes 7a and 8a, the proposed structures were corroborated by XRD analyses (Fig. 2). In this respect, suitable crystals were obtained by slow evaporation of diethylether in a dichloromethane solution of the palladium complex.
Scheme 2D also illustrates our attempts to coordinate a PTA-based ligand to the [PdCl(η3-allyl)] fragment. Pd(II)-allyl complexes usually exhibit high cytotoxicity against a broad spectrum of cancer cell lines. However, only a subset of these complexes shows good selectivity towards cancer cells.40,46 Many of these contain a Pd(II)-allyl fragment, one N-heterocyclic carbene (NHC), and one PTA ligand. These complexes, with the general formula [Pd(NHC)(PTA)(η3-allyl)]X (X = BF4, ClO4, OTf), induce cancer cell death through an apoptotic mechanism involving early mitochondrial damage. Moreover, recent studies have demonstrated that such organopalladium derivatives significantly inhibit key proteins involved in cellular redox balance, such as thioredoxin reductase (TrxR).59,60
The crucial role of PTA in ensuring good selectivity for the Pd(II)-allyl complexes, prompted us to explore the simple reaction between PTA and the commercially available dimeric precursor [PdCl(η3-allyl)]2 (compound 9 in Scheme 2D), aiming to synthesize the neutral complex [PdCl(PTA)(η3-allyl)] (10a). This reaction represents the cleavage of the palladium dimeric precursor and the simultaneous coordination of the external ligand.
To our surprise, despite numerous attempts, we constantly obtained a mixture of products that were difficult to identify, whereas the same reaction with classical tertiary phosphines (e.g., PPh3) yielded clean products. Evidently, compound 10a is either not stable, or parasitic reactions are preventing its formation.
However, when the cationic derivative [Me-PTA]PF6 (b) was chosen as ligand in the same reaction, the target complex 10b was obtained without further purification. We therefore hypothesize that the charge of the complex is essential for stabilizing this class of organopalladium derivatives.
The 31P NMR spectrum of complex 10b shows a singlet at ca. −39 ppm (Δδ ≈ 48 ppm with respect to the free PTA ligand), as well as the septet of the PF6− counterion at −144 ppm. In the 1H NMR spectrum, it is possible to observe the signals of the methyl protons of the ligand (2.2 ppm) and those of the methylene protons NCH2N and NCH2P (multiplets at 4–5 ppm). Regarding the allyl moiety, the multiplet at ca. 5.6 ppm is assigned to the central allyl proton, whereas the multiplets for the anti-allyl protons are observed at 3.2–3.6 ppm, and those of the syn-allyl protons are detected at 4.3–4.6 ppm.
Following a procedure similar to that used for the synthesis of neutral complexes 12a and 14a, their dicationic congeners 12b and 14b were obtained. Specifically, a direct reaction was performed between palladium precursors 11 and 13 and two equivalents of [Me-PTA]PF6 (b) in acetonitrile at room temperature.
The 31P NMR spectra of complexes 12b and 14b showed a singlet at −49 and −43 ppm, respectively (Δδ ≈ 40 ppm with respect to the free [Me-PTA]PF6 ligand), as well as the septet of the PF6− counterion at −144 ppm.
In the 1H NMR spectrum of complex 12b, the methyl protons of the imidoyl fragment and the PTA-based ligands are observed at 2.1–2.8 ppm, the methylene protons NCH2N and NCH2P appear as multiplets between 4 and 5 ppm, and the aromatic protons are detectable at 7–7.5 ppm.
For what concerns the 1H NMR spectrum of complex 14b, in addition to the signals of aromatic protons and those of the PTA-based ligands, the ones of the two olefinic protons are particularly noteworthy, resonating as multiplets between 3.9 and 4.3 ppm. In fact, these protons resonate at 7–8 ppm in the case of free (E)-1,2-ditosylethene, thus confirming the coordination of both the phosphine ligand and the alkene to the palladium metal center. The choice of this olefin is due to its ability to form a very robust bond with palladium, attributed to strong back-donation. The high stability of Pd(0)–(E)-ditosylethene derivatives is expected to reduce or prevent the hydrolysis of the complex before it reaches the biotarget.
Preliminarily, we have monitored the stability of the organopalladium complexes in a solution containing ca. 2 mg of Pd complex dissolved in a DMSO/H2O mixture (0.15 mL: 250 mL) with 1.46 g of NaCl (0.1 M). After 24 h no significant changes of the spectra are detectable, indicating that the complexes retain their structural integrity. We have additionally monitored the stability in a 1:
2 culture medium/DMSO-d6 solution by 31P NMR (Fig. S51–S61 in ESI†). The complexes were stable even under these conditions.
The antiproliferative activity results for the tested compounds are reported in Table 1 in terms of half inhibitory concentrations (IC50) values.
Compound | IC50 (μM) | ||||
---|---|---|---|---|---|
A2780 | A2780cis | MDA-MB-231 | U87 | MRC-5 | |
a Data after 96 h of incubation. Stock solutions in DMSO for all complexes; stock solutions in H2O for cisplatin. A2780 (cisplatin-sensitive ovarian cancer cells), A2780cis (cisplatin-resistant ovarian cancer cells), MDA-MB-231 (triple-negative breast cancer), U87 (glioblastoma) and MRC-5 (normal lung fibroblasts). | |||||
Cisplatin | 2.7 ± 0.3 | 45 ± 5 | 10 ± 1 | 10.4 ± 0.4 | 4 ± 1 |
3a (ref. 39) | 0.17 ± 0.04 | 2.2 ± 0.3 | 0.3 ± 0.1 | — | >100 |
3b | 3.4 ± 0.4 | 0.56 ± 0.08 | 14 ± 2 | 80 ± 10 | >100 |
3c | 2.7 ± 0.2 | 2.1 ± 0.2 | 15 ± 2 | >100 | >100 |
3d | 1.3 ± 0.3 | 1.3 ± 0.2 | 9 ± 1 | 60 ± 10 | >100 |
3e | 2.9 ± 0.1 | 2.2 ± 0.1 | 14 ± 1 | 80 ± 10 | >100 |
4a (ref. 39) | 0.08 ± 0.04 | 0.6 ± 0.4 | 0.10 ± 0.01 | — | >100 |
4b | 3.3 ± 0.5 | 0.44 ± 0.08 | 9 ± 1 | 70 ± 10 | >100 |
4c | 3.0 ± 0.6 | 0.90 ± 0.08 | 9 ± 2 | 80 ± 10 | >100 |
4d | 0.55 ± 0.09 | 0.33 ± 0.05 | 80 ± 10 | 90 ± 20 | 90 ± 10 |
4e | 0.29 ± 0.02 | 0.43 ± 0.07 | 10 ± 1 | 15 ± 6 | 70 ± 10 |
7a | 0.31 ± 0.02 | 0.29 ± 0.07 | 0.50 ± 0.04 | 80 ± 20 | >100 |
7b | 3.1 ± 0.3 | 0.18 ± 0.02 | 6.7 ± 0.9 | 90 ± 10 | >100 |
8a | 0.43 ± 0.09 | 0.31 ± 0.03 | 0.6 ± 0.2 | 30 ± 10 | >100 |
10b | 3.7 ± 0.2 | 1.9 ± 0.5 | 15 ± 2 | 15 ± 5 | >100 |
12a (ref. 47) | 30 ± 10 | 41 ± 5 | — | — | — |
12b | 4.7 ± 0.4 | 3.5 ± 0.2 | 80 ± 10 | 60 ± 10 | 80 ± 10 |
14a (ref. 61) | 0.7 ± 0.3 | 0.7 ± 0.1 | — | — | — |
14b | 0.61 ± 0.04 | 0.35 ± 0.05 | 3.1 ± 0.3 | 3.0 ± 0.2 | 80 ± 10 |
Analyzing the data obtained from A2780 cisplatin-sensitive ovarian cancer cells, it is evident that all the compounds synthesized in this study exhibit cytotoxicity comparable to or greater than cisplatin, with some showing up to an order of magnitude higher activity. Notably, among compounds with the same phosphine ligand, the Pd(II)-butadienyl complexes (4a–e) are generally more active than their Pd(II)-vinyl counterparts (3a–e). Within the Pd(II)-butadienyl series, the phosphine ligand exerts a significant influence; complexes containing PTA or its cationic derivatives (d–e) demonstrate higher activity compared to those with ligands b and c. Similarly, among the Pd(II)-aryl complexes, those containing PTA (7a and 8a) are more active than the dicationic derivative 7b. Nevertheless, 7b still exhibits good cytotoxicity, comparable to that of cisplatin.
For Pd(II)-imidoyl and Pd(0)-alkene complexes (12a–b and 14a–b), the dicationic compounds (12b and 14b) display cytotoxicity comparable to or even greater than their neutral congeners.
Even more interesting are the results obtained with cisplatin-resistant ovarian cancer cells (A2780cis). All the compounds, except for 12a, show cytotoxicity that is one or two orders of magnitude higher than that of cisplatin. As observed on A2780 cancer cells, the Pd(II)-butadienyl (4a–e), Pd(II)-aryl (7a–b and 8a), and Pd(0)-alkene (14a–b) complexes are more active than their Pd(II)-vinyl (3a–e), Pd(II)-allyl (10b), and Pd(II)-imidoyl (12a–b) congeners.
When exploring a completely different cancer model, such as triple-negative breast cancer cells (MDA-MB-231), the results highlight the high efficacy of complexes containing unfunctionalized PTA (3a, 4a, 7a, 8a), regardless of the type of organopalladium fragment. The cationic complexes (3b–e, 4b–c, 4e, 7b, 10b, and 14b) also demonstrate good cytotoxicity, comparable to that of cisplatin, while derivatives 4d and 12b are scarcely active.
Although the ovarian cancer and triple-negative breast cancer cells revealed good to excellent cytotoxicity for the complexes investigated in this study, this trend does not extend to glioblastoma (U87) cells. The IC50 values presented in Table 1 show that most compounds are poorly active or inactive against this tumor type. Exceptions include complexes 4e, 10b, and 14b, which exhibit cytotoxicity comparable to or exceeding that of cisplatin.
Given that most of the analysed compounds show selectivity toward ovarian and breast cancer cells, we also investigated their cytotoxicity against non-cancerous cells (MRC-5). To our delight and surprise, nearly all compounds are poorly active or inactive against normal cells, highlighting their pronounced in vitro selectivity. In contrast, cisplatin exhibits comparable cytotoxicity towards both cancerous and non-cancerous cells.
To better understand the binding interactions between DNA and the fully optimized structure of 8a, we carried out molecular docking simulations.
The palladium complex binds in the minor groove of the DNA and exhibits hydrogen bonds (H-bonds), carbon–hydrogen (C–H) bonds, and Pd⋯O intermolecular interactions (Fig. 3). These interactions are crucial for stabilizing the ligand–receptor complex both geometrically and energetically. In fact, the predicted binding free energy (ΔG) of −6.9 kcal mol−1 suggests that 8a has a higher affinity for DNA than another palladium complex ([PdI(Ph)(dppe)]) from our previous study,49 which is nicely consistent with its superior cytotoxicity. The H-bond forms between a deoxyguanosine residue (dG22) of DNA and the nitrogen atom of 8a, while the two C–H bond interactions involve the trifluoromethyl group of 8a and the C–H moieties of the DNA sugar backbone.
Additionally, the Lewis acid–base interaction — specifically, the interaction between the palladium metal and the oxygen atom of the sugar in the dC23 residue (Pd⋯O) — plays an important role in the binding pose of the molecule, orienting the Pd–I moiety (polar region of the ligand) toward the solvent-accessible area (water) and outside the DNA hydrophobic groove.
A variety of organopalladium fragments were explored, including Pd(II)-vinyl, Pd(II)-butadienyl, Pd(II)-allyl, Pd(II)-imidoyl, Pd(II)-aryl, and Pd(0)-alkene, which have recently demonstrated promising antiproliferative activity against various cancer cell lines. Reactions between PTA-based ligands and the different palladium precursors investigated proceed within 30 min at room temperature under aerobic conditions, utilizing non-anhydrous acetonitrile or dichloromethane as solvents.
Interestingly, in the case of the Pd(II)-allyl fragment, the PTA derivative proved unstable and could not be isolated. Conversely, the cationic derivative incorporating MePTA+ as a ligand was isolable and sufficiently stable to allow biological testing.
All newly synthesized compounds were fully characterized by 1H, 13C, and 31P NMR spectroscopy and elemental analyses. For complexes 7a and 8a, their structures were further confirmed by single-crystal X-ray diffraction analysis.
To evaluate the antitumor potential of organopalladium complexes with PTA-based ligands, we tested them on four human tumor cell lines—A2780 ovarian cancer, its cisplatin-resistant clone A2780cis, MDA-MB-231 triple-negative breast cancer, and U87 glioblastoma—as well as on MRC-5 non-cancerous cells. The IC50 values highlight the remarkable cytotoxicity (in the micro- or submicro-molar range) of all tested organopalladium compounds against ovarian cancer and triple-negative breast cancer cells. This cytotoxicity is comparable to or significantly higher than that of cisplatin (reference drug) with some compounds showing activity up to two orders of magnitude greater. Among the tested categories, complexes featuring Pd(II)-butadienyl, Pd(II)-aryl, and Pd(0)-alkene fragments proved more active than those containing Pd(II)-vinyl, Pd(II)-allyl, and Pd(II)-imidoyl fragments.
For a given organopalladium fragment, complexes containing PTA as a ligand generally displayed higher activity compared to those with cationic PTA ligands. Curiously, nearly all tested compounds exhibited minimal or no activity (IC50 > 100 μM) against non-cancerous MRC-5 human lung fibroblasts, proving high in vitro selectivity for cancer cells over normal ones. In contrast, as reported in previous studies, cisplatin exhibited comparable cytotoxicity towards both cancerous and normal cells.
A downside of this work deals with the results obtained on the glioblastoma cell line (U87), where only complexes 4e, 10b, and above all 14b displayed an encouraging cytotoxicity (IC50 = 3–15 μM).
Overall, we consider complexes 7a, 8a, and 14b to be the most promising, alongside some previously investigated compounds (3a and 4a). Molecular docking simulations between DNA and 8a revealed that the interaction with the minor groove is stabilized by hydrogen bonds, C–H interactions, and a Pd⋯O Lewis acid–base interaction, contributing to a favourable binding free energy of −6.9 kcal mol−1. These findings are consistent with the higher cytotoxicity of 8a compared to previously studied Pd(II)-aryl complexes, highlighting its potential as a biologically active compound.
Complex 14b is also particularly interesting as it is the only one that presents palladium in the zerovalent state, which is decidedly less explored in medicinal chemistry compared to Pd(II) complexes, and it is the only one active on all the investigated tumor cell lines, including glioblastoma.
Based on these promising results, further in vitro and in vivo experiments, as well as detailed mechanistic studies, are currently underway in our laboratories.
Palladium precursors 1–2,62 5–6,63,64 11,47 13 (ref. 61) were synthesized according to published protocols.
1D-NMR and 2D-NMR spectra were recorded on Bruker 300 or 400 Advance spectrometers. Chemical shifts values (ppm) are given relative to TMS (1H and 13C), H3PO4 (31P) and CCl3F (19F). Elemental analyses were carried out using an Elemental CHN “CUBO Micro Vario” analyzer.
The iodide counterion was replaced by hexafluorophosphate by dissolving the white solid in 15 mL of distilled water in the presence of 0.5330 g (2.895 mmol) of KPF6. The solution was kept at room temperature for 30 min and then filtered in a sintered glass filter. The final product was dried under vacuum and obtained as white solid (0.4940 g, yield = 70%).
1H NMR (300 MHz, DMSO-d6, 298 K, ppm) δ: 2.58 (s, 3H, NCH3), 3.71–4.94 (m, 12H, NCH2N, NCH2P).
31P{1H}-NMR (121 MHz, DMSO-d6, 298 K, ppm) δ: −87.0, −144.2 (sept, J = 701 Hz, PF6−).
The bromide counterion was replaced by hexafluorophosphate by dissolving the white solid in 20 mL of distilled water in the presence of 0.4133 g (2.895 mmol) of KPF6. The solution was kept at room temperature for 30 min and then filtered in a sintered glass filter. The final product was dried under vacuum and obtained as white solid (0.4102 g, yield = 61%).
1H NMR (300 MHz, DMSO-d6, 298 K, ppm) δ: 2.08 (s, 3H, CH3), 3.76–4.60 (m, 12H, NCH2N, NCH2P), 4.84–5.09 (m, 4H, NCH2CH2O).
31P{1H}-NMR (121 MHz, DMSO-d6, 298 K, ppm) δ: −85.3, −144.2 (sept, J = 711.3 Hz, PF6−).
The bromide counterion was replaced by hexafluorophosphate by dissolving the white solid in 15 mL of distilled water in the presence of 0.2304 g (1.252 mmol) of KPF6. The solution was kept at room temperature for 30 min and then filtered in a sintered glass filter. The final product was dried under vacuum and obtained as a white solid (0.3586 g, yield = 82%).
1H NMR (300 MHz, DMSO-d6, 298 K, ppm) δ: 3.92–3.77 (m, 4H, NCH2P), 4.14 (s, 2H, NCH2Ph), 4.24 (d, J = 5.8 Hz, 2H, NCH2P), 4.55 and 4.35 (AB system, JAB = 12.0 Hz, 2H, NCH2N), 5.03 and 4.87 (AB system, JAB = 12.0 Hz, 4H, NCH2N), 8.07 and 7.63 (m, 4H, Ar–H).
31P{1H}-NMR (121 MHz, DMSO-d6, 298 K, ppm) δ: −83.4, −144.1 (sept, J = 711.2 Hz, PF6−).
The bromide counterion was replaced by hexafluorophosphate by dissolving the white solid in 15 mL of distilled water in the presence of 0.2306 g (1.252 mmol) of KPF6. The solution was kept at room temperature for 30 min and then filtered in a sintered glass filter. The final product was dried under vacuum and obtained as a white solid (0.3458 g, yield = 79%).
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 3.73–3.96 (m, 4H, NCH2P), 4.00 (s, 2H, NCH2Ph), 4.11–4.14 (m, 2H, NCH2P), 4.38–4.58 (m, 2H, NCH2N), 4.77–4.89 (m, 4H, NCH2N), 7.13–7.83 (3H, Ar–H), 10.32 (d, J = 0.6 Hz, 1H, CHO), 11.12 (s, 1H, OH).
31P{1H}-NMR (121 MHz, DMSO-d6, 298 K, ppm) δ: −82.6, −144.6 (sept, J = 711.2 Hz, PF6−).
1H NMR (300 MHz, CDCl3, 298 K, ppm) δ: 4.00 (s, 12H, PCH2N), 4.32–4.45 (m, 12H, NCH2N), 7.40 (d, 2H, J = 8.2 Hz, Ar–H), 8.02 (d, 2H, J = 8.2 Hz, Ar–H).
13C{1H}-NMR (75 MHz, CDCl3, 298 K, ppm) δ: 52.1 (CH2, t, JC–P = 7.4 Hz, PCH2N), 73.2 (CH2, t, JC–P = 3.6 Hz, NCH2N), 122.3 (CH, Ar–CH), 136.0 (CH, t, JC–P = 4.8 Hz, Ar–CH), 145.8 (C, p-Ar–C), 163.8 (C, t, JC–P = 7.5 Hz, i-Ar–C).
31P{1H}-NMR (121 MHz, CDCl3, 298 K, ppm) δ: −69.5.
Elemental analysis calcd (%) for C18H28IN7O2P2Pd: C, 32.28, H, 4.21, N, 14.64; found: C, 32.57, H, 4.04, N, 14.73.
1H NMR (300 MHz, CDCl3, 298 K, ppm) δ: 3.99 (s, 12H, PCH2N), 4.33–4.44 (m, 12H, NCH2N), 7.28 (d, 2H, J = 8.1 Hz, Ar–H), 7.40 (d, 2H, J = 7.8 Hz, Ar–H).
13C{1H}-NMR (75 MHz, CDCl3, 298 K, ppm) δ: 52.0 (CH2, t, JC–P = 7.4 Hz, PCH2N), 73.2 (CH2, t, JC–P = 3.3 Hz, NCH2N), 124.9 (CH, q, JC–F = 3.7 Hz, Ar–CH), 126.6 (C, q, JC–F = 27.5 Hz, p-Ar–C), 135.9 (CH, t, JC–P = 4.8 Hz, Ar–CH), 155.3 (C, t, JC–P = 6.7 Hz, i-Ar–C).
31P{1H}-NMR (121 MHz, CDCl3, 298 K, ppm) δ: −69.3.
Elemental analysis calcd (%) for C19H28F3IN6P2Pd: C, 32.94, H, 4.07, N, 12.13; found: C, 32.70, H, 4.15, N, 12.24.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.96 (s, 3H, CCH3), 2.76 (s, 6H, NCH3), 3.67 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 4.07–4.95 (m, 24H, NCH2N, NCH2P).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 171.6, 162.9, 129.1, 80.9, 69.1, 54.7, 52.1, 51.9, 51.5, 51.4, 49.3, 46.4, 46.3, 40.4, 22.1.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −43.6, −144.6 (sept, J = 701 Hz, PF6−).
Elemental analysis calcd (%) for C21H39ClF12N6O4P4Pd: C, 27.02, H, 4.21, N, 9.00; found: C, 26.85, H, 4.29, N, 9.11.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.96 (s, 3H, CCH3), 2.12 (s, 6H, O–COCH3), 3.26–3.38 (m, 4H, N+C
2CH2O), 3.67 (s, 3H, OCH3) 3.78 (s, 3H, OCH3), 4.11–5.12 (m, 24H, NCH2N, NCH2P), 4.37–4.42 (m, 4H, N+CH2C
2O).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 170.3, 169.8, 129.0, 82.6, 80.6, 73.2, 59.8, 51.4, 49.2, 40.4, 19.9.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −42.2, −144.6 (sept, J = 718 Hz, PF6−).
Elemental analysis calcd (%) for C27H47ClF12N6O8P4Pd: C, 30.10, H, 4.40, N, 7.80; found: C, 30.46, H, 4.25, N, 7.71.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.96 (s, 3H, CCH3), 2.05 (s, 4H, CH2), 3.60 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 3.89–4.90 (m, 24H, NCH2N, NCH2P), 7.16 (d, 2H, J = 8.53 Hz, Ar–H) 7.59 (d, 2H, J = 8.41 Hz, Ar–H), 7.78 (s, 2H, Ar–H), 10.02 (s, 2H, CHO), 11.12 (s, 2H, OH).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 192.4, 172.0, 166.2, 133.2, 130.7, 130.4, 130.2, 129.4, 129.1, 127.0, 82.7, 80.9, 51.1, 49.3, 46.3, 40.2, 18.2.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −40.3, −144.5 (sept, J = 693 Hz, PF6−).
Elemental analysis calcd (%) for C35H47ClF12N6O8P4Pd: C, 35.82, H, 4.04, N, 7.16; found: C, 36.07, H, 3.91, N, 7.03.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.97 (s, 3H, CCH3), 2.02 (s, 4H, CH2), 2.23 (bs, 1H, COOH), 3.59 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 3.89–5.05 (m, 24H, NCH2N, NCH2P), 7.14–7.41 (m, Ar–H), 7.56 (d, J = 7.60 Hz, Ar–H), 8.15 (d, J = 7.83 Hz, Ar–H).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 197.4, 190.3, 165.7, 162.8, 140.7, 138.7, 136.8, 136.7, 135.1, 132.5, 129.5, 121.2, 121.0, 120.7, 82.7, 80.9, 79.4, 79.3, 69.3, 64.6, 51.6, 51.5, 50.7, 49.3, 46.3, 40.3, 22.1.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −40.1, −144.6 (sept, J = 705 Hz, PF6−).
Elemental analysis calcd (%) for C35H47ClF12N6O8P4Pd: C, 35.82, H, 4.04, N, 7.16; found: C, 35.60, H, 4.12, N, 7.21.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.8–2.0 (m, 3H, CCH3), 2.8 (s, 6H, NCH3), 3.72 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.11–4.99 (m, 24H, NCH2N, NCH2P).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 169.0, 161.7, 138.2, 134.2, 81.1, 69.2, 54.8, 53.2, 52.7, 52.2, 49.3, 46.4, 40.4, 17.5.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −42.2, −144.6 (sept, J = 706.5 Hz, PF6−).
Elemental analysis calcd (%) for C27H45ClF12N6O8P4Pd: C, 30.15, H, 4.22, N, 7.81; found: C, 30.40, H, 4.08, N, 7.71.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.8–2.0 (s, 3H, CCH3), 2.13 (s, 6H, OCOCH3), 3.34 (s, 4H, NCH2N), 3.72 (s, 3H, OCH3), 3.74 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 4.08–4.35 (m, 8H, CH2CH2), 4.37–4.61 (m, 12H, NCH2P), 4,99 (m, 8H, NCH2N).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 171.1, 171.0, 162.4, 139.1, 83.7, 83.6, 81.8, 74.0, 60.4, 53.5, 53.1, 49.9, 41.1, 20.7, 18.3.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −40.1, −144.6 (sept, J = 706.3 Hz, PF6−).
Elemental analysis calcd (%) for C33H53ClF12N6O12P4Pd: C, 32.50, H, 4.38, N, 6.89; found: C, 32.14, H, 4.50, N, 6.98.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.79 (s, 3H, CCH3), 3.69 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 3.73 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 4.15-4-60 (m, 16H, NCH2N, NCH2P), 4.80–5.01 (m, 8H, NCH2N, NCH2P), 4.89 (s, 2H, OH), 7.13–7.19 (d, 2H, J = 8.6 Hz, Ar–H), 7.57–7.65 (dd, 2H, J = 8.6 Hz, J = 2.3 Hz, Ar–H), 7.77–7.82 (d, 2H, J = 2.3 Hz, Ar–H), 10.02 (s, 2H, CHO).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 192.9, 166.7, 166.5, 138.4, 133.8, 131.3, 131.0, 130.8, 130.0, 129.6, 127.5.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: 38.9, −144.6 (sept, J = 706.6 Hz, PF6−).
Elemental analysis calcd (%) for C41H53ClF12N6O12P4Pd: C, 37.43, H, 4.06, N, 6.39; found: C, 37.61, H, 3.98, N, 6.48.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 1.77 (s, 3H, CCH3), 3.65 (s, 3H, OCH3), 3.71 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 4.22–5.06 (m, 24H, NCH2N, NCH2P), 7.13–7.61 (m, 8H, Ar–H).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 197.4, 190.1, 165.7, 162.8, 140.7, 138.7, 136.8, 129.5, 121.1, 79.6, 69.4, 65.3, 53.2, 52.7, 52.2, 46.7, 40.4, 17.4, 14.6.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −38.9, −144.6 (sept, J = 706.2 Hz, PF6−).
Elemental analysis calcd (%) for C41H53ClF12N6O12P4Pd: C, 37.43, H, 4.06, N, 6.39; found: C, 37.30, H, 4.12, N, 6.53.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 2.56 (s, 6H, NCH3), 3.89–4.82 (m, 24H, NCH2N, NCH2P), 7.58 (d, J = 8.7 Hz, Ar–H), 8.06 (d, J = 8.7 Hz, Ar–H).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 47.4 (CH2, PTACH2), 49.0 (CH3, NCH3), 56.2 (CH2, PTACH2), 68.9 (CH2, PTACH2), 80.7 (CH2, PTACH2), 122.6 (CH, Ar–CH), 136.7 (CH, Ar–CH), 146.4 (C, p-Ar–C), 157.1 (C, i-Ar–C).
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −50.8, −144.6 (sept, J = 706.8 Hz, PF6−).
Elemental analysis calcd (%) for C20H34F12IN7O2P4Pd: C, 24.27, H, 3.46, N, 9.91; found: C, 24.50, H, 3.33, N, 9.99.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 2.17 (s, 3H, NCH3), 3.28–3.62 (m, 1H, Hanti), 3.28–3.62 (m, 1H, Hanti), 4.02–5.01 (m, 12H, NCH2N, NCH2P), 4.36–4.61 (m, 1H, Hsyn), 4.36–4.61 (m, 1H, Hsyn), 5.45–5.60 (m, 1H, Hcentral).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 80.9, 69.2, 56.0, 49.3, 47.3, 47.2.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −39.2, −144.6 (sept, J = 706.3 Hz, PF6−).
Elemental analysis calcd (%) for C10H20ClF6N3P2Pd: C, 24.02, H, 4.03, N, 8.40; found: C, 23.85, H, 4.10, N, 8.52.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 2.18 (bs, 3H, NCCH3) 2.21 (s, 3H, Ar–CH3), 2.22 (s, 3H, Ar–CH3), 2.68 (s, 6H, NCH3), 4.02–4.99 (m, 24H, NCH2N, NCH2P) 7.02–7.43 (m, 3H, Ar–H).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 172.8, 167.0, 140.4, 137.0, 130.0, 129.6, 128.3, 128.1, 125.6, 81.2, 68.5, 60.0, 59.3, 52.7, 51.9, 49.1, 18.0, 17.3, 14.8.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −49.3, −144.5 (sept, J = 708 Hz, PF6−).
Elemental analysis calcd (%) for C24H42ClF12N7P4Pd: C, 31.25, H, 4.59, N, 10.63; found: C, 31.48, H, 4.37, N, 10.72.
1H NMR (300 MHz, CH3CN-d3, 298 K, ppm) δ: 2.41 (s, 6H, Ar–CH3), 2.77 (s, 6H, NCH3), 3.92–4.25 (m, 2H, CHCH), 4.14–5.02 (m, 24H, NCH2N, NCH2P), 7.04–7.11 (d, 4H, J = 8.1 Hz, Ar–H), 7.30–7.38 (d, 4H, J = 8.1 Hz, Ar–H).
13C{1H}-NMR (75 MHz, CH3CN-d3, 298 K, ppm) δ: 143.6, 129.7, 126.3, 81.1, 69.4, 58.4, 49.6, 49.0, 20.7.
31P{1H}-NMR (121 MHz, CH3CN-d3, 298 K, ppm) δ: −42.8, −144.6 (sept, J = 706.7 Hz, PF6−).
Elemental analysis calcd (%) for C30H46F12N6O4P4PdS2: C, 33.45, H, 4.30, N, 7.80; found: C, 33.70, H, 4.11, N, 7.89.
Thermal motions for all non-hydrogen atoms have been treated anisotropically and hydrogens have been included at calculated positions, riding on their carrier atoms. Geometric and thermal restraints (DFIX, DANG and SIMU) have been used to model disordered –CF3 group in 8a. The Coot program was used for structure building.69 Pictures were prepared using Ortep3 (ref. 70) and Pymol71 software.
Crystallographic data have been deposited at the Cambridge Crystallographic Data Centre and allocated deposition numbers CCDC 2411281 and 2411282, for 8a and 7a respectively.
Footnote |
† Electronic supplementary information (ESI) available. CCDC 2411281 and 2411282. For ESI and crystallographic data in CIF or other electronic format see DOI: https://doi.org/10.1039/d5ra02119g |
This journal is © The Royal Society of Chemistry 2025 |